Literature DB >> 21508409

B-cell receptors and heavy chain diseases: guilty by association?

Daniel Corcos1, Michael J Osborn, Louise S Matheson.   

Abstract

Heavy chain diseases (HCDs) are B-cell proliferative disorders characterized by the production of monoclonal, incomplete, immunoglobulin (Ig) heavy chains (HCs) without associated light chains (LCs). These abnormal HCs are produced as a consequence of HC gene alterations in the neoplastic B cells. HC gene alterations will also impact on surface HC, which is part of the B-cell receptor (BCR), a crucial player in lymphocyte activation by antigen. The selective advantage conferred to mutant cells by abnormal BCR without an antigen-binding domain may be explained by activation of ligand-independent signaling, in analogy to what has been shown for mutated oncogenic growth factor receptors. Here we review data obtained from mouse models showing abnormal, constitutive activity of HCD-BCR, and we discuss the possible mechanism involved, namely, aberrant spontaneous self-aggregation. This self-aggregation might occur as a consequence of escape from the chaperone immunoglobulin binding protein (BiP) and from the anti-aggregation effect of LC association. The concept of misfolding-induced signaling elaborated here may extend to other pathologies termed conformational diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508409     DOI: 10.1182/blood-2011-02-336164

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases.

Authors:  Shannon Bieliauskas; Raymond R Tubbs; Chris M Bacon; Camellia Eshoa; Kathryn Foucar; Sarah E Gibson; Steven H Kroft; Aliyah R Sohani; Steven H Swerdlow; James R Cook
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Gamma 1-heavy chain deposition disease accompanied by IgG kappa in serum, urine, and bone marrow.

Authors:  Keiichi Kaneko; Koichi Seta; Jun Soma; Takashi Kuwahara; Mitsuteru Koizumi; Yuko Kikuchi; Akira Sugawara; Kensei Yahata
Journal:  CEN Case Rep       Date:  2013-07-10

Review 3.  Heavy Chain Disease of the Small Bowel.

Authors:  Giada Bianchi; Aliyah R Sohani
Journal:  Curr Gastroenterol Rep       Date:  2018-01-25

4.  Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Authors:  Denise K Walters; Bonnie K Arendt; Renee C Tschumper; Xiaosheng Wu; Diane F Jelinek
Journal:  Exp Hematol       Date:  2017-10-13       Impact factor: 3.084

5.  B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Borja G Cosio; Jaime Pons; Maria Laucho-Contreras; Paula Tejera; Amanda Iglesias; Angel Rios; Andreas Jahn; Jaume Sauleda; Miguel Divo; Victor Pinto-Plata; Lynette Sholl; Ivan O Rosas; Alvar Agustí; Bartolome R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

6.  Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology.

Authors:  Haruki Hasegawa
Journal:  Int J Cell Biol       Date:  2013-03-05

Review 7.  Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update.

Authors:  Roberto Ria; Franco Dammacco; Angelo Vacca
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.